Taysha Gene Therapies Inc

$15.75 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a gene therapy company focused on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Its product candidates include: TSHA-101, which is being developed for the treatment of GM2 gangliosidosis; TSHA-118, which is a AAV9 viral vector that expresses human codon-optimized Ceroid Lipofuscinosis Neuronal 1 complementary deoxyribonucleic acid under control of the chicken b-actin hybrid promoter; TSHA-102, which is being developed for the treatment of Rett syndrome; TSHA-103, which is being developed for the treatment of Solute Carrier Family 6 Member 1 (SLC6A1) haploinsufficiency disorder, and TSHA-104, which is being developed for the treatment for Surfeit locus 1.

Stock Analysis

last close $15.75
1-mo return -17%
3-mo return -19.3%
avg daily vol. 82.89T
52-week high 33.35
52-week low 15.5
market cap. $686M
forward pe -
annual div. -
roe -133.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 45.8%
baraka

Subscribe now for daily local and international financial news

Subscribe